Putative impact of RNA editing on drug discovery

Chem Biol Drug Des. 2013 Jan;81(1):13-21. doi: 10.1111/cbdd.12045.


Virtually all organisms use RNA editing as a powerful post-transcriptional mechanism to recode genomic information and to increase functional protein diversity. The enzymatic editing of pre-mRNA by ADARs and CDARs is known to change the functional properties of neuronal receptors and ion channels regulating cellular excitability. However, RNA editing is also an important mechanism for genes expressed outside the brain. The fact that RNA editing breaks the 'one gene encodes one protein' hypothesis is daunting for scientists and a probable drawback for drug development, as scientists might search for drugs targeting the 'wrong' protein. This possible difficulty for drug discovery and development became more evident from recent publications, describing that RNA editing events have profound impact on the pharmacology of some common drug targets. These recent studies highlight that RNA editing can cause massive discrepancies between the in vitro and in vivo pharmacology. Here, we review the putative impact of RNA editing on drug discovery, as RNA editing has to be considered before using high-throughput screens, rational drug design or choosing the right model organism for target validation.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Calcium Channels, L-Type / genetics
  • Calcium Channels, L-Type / metabolism
  • Drug Discovery*
  • Humans
  • Kv1.1 Potassium Channel / genetics
  • Kv1.1 Potassium Channel / metabolism
  • Pharmaceutical Preparations / metabolism
  • RNA Editing / genetics*
  • Receptor, Serotonin, 5-HT2C / genetics
  • Receptor, Serotonin, 5-HT2C / metabolism
  • Receptors, AMPA / genetics
  • Receptors, AMPA / metabolism
  • Receptors, GABA / genetics
  • Receptors, GABA / metabolism


  • CACNA1D protein, human
  • Calcium Channels, L-Type
  • Pharmaceutical Preparations
  • Receptor, Serotonin, 5-HT2C
  • Receptors, AMPA
  • Receptors, GABA
  • Kv1.1 Potassium Channel
  • glutamate receptor ionotropic, AMPA 2